- Enliven's ELVN-001 is a high-potential investigational therapy with a best-in-class profile, offering a complementary mechanism to the approaches of Novartis’s Asciminib and TERN-701, the analyst said.
- Clear sees ELVN-001 as a lower-risk, high-upside asset.
- The late-stage ENABLE-2 trial of ELVN-001 in second line and beyond CML remains on track for the second half of 2026 initiation.
Shares of Enliven Therapeutics Inc (ELVN) rallied 15% on Wednesday after Wall Street highlighted that Merck's (MRK) $6.7 billion acquisition of Terns Pharmaceuticals' (TERN) TERN-701 underscores the unmet need and opportunity for safer, more effective chronic myeloid leukemia (CML) therapies, similar to the kind Enliven is developing.
Clear Street noted the opportunity for CML therapies despite generics. The acquisition signals growing interest in CML beyond Novartis (NVS), it added. Chronic myeloid leukemia (CML) is a slow-growing blood cancer where the bone marrow produces too many myeloid cells.
In this context, Enliven's ELVN-001 is a high-potential investigational therapy with a best-in-class profile, offering a complementary mechanism to the approaches of Novartis’s Asciminib and TERN-701 and multiple strategic paths to value, the firm argued.
Clear sees ELVN-001 as a lower-risk, high-upside asset. The late-stage ENABLE-2 trial of ELVN-001 in second line and beyond CML remains on track for the second half of 2026 initiation, pending U.S. Food and Drug Administration’s alignment on dose selection and trial design.
Merck-Terns Deal
Merck said earlier on Wednesday that it has entered into a definitive agreement to acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion in a bid to add TERN-701 to its portfolio. TERN-701 is an experimental therapy currently in development for certain patients with CML. The transaction is expected to close in the second quarter of 2026, the company said, but analysts including RBC Capital and William Blair noted that it expects another bidder to emerge for Terns.
How Did Stocktwits Users React?
On Stocktwits, retail sentiment around ELVN stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.
ELVN stock has gained 68% over the past 12 months.
Read More: Salesforce Reportedly Holding Back On Raises For Higher-Level Employees
For updates and corrections, email newsroom[at]stocktwits[dot]com.